BMO downgrades Replimune stock on FDA rejection concerns - Stock Watch Index

BMO downgrades Replimune stock on FDA rejection concerns

April 13, 2026

BMO downgrades Replimune stock on FDA rejection concerns

Search

RECENT PRESS RELEASES

Should New Analyst Coverage of SharpLink’s Dual Sports Betting and Ethereum Model Require Action From SBET Investors?

SWI Editorial Staff2026-04-13T03:06:10-07:00April 13, 2026|

Brazil’s electricity regulator ANEEL delays energy storage rulemaking, approves hybrid solar-BESS

SWI Editorial Staff2026-04-13T02:10:39-07:00April 13, 2026|

Amazon Has Become an E-commerce and Cloud Computing Behemoth. Now It’s Set Its Sights on Another Billion-Dollar Market. And It Could Spell Trouble for Nvidia.

SWI Editorial Staff2026-04-13T02:02:00-07:00April 13, 2026|

SpaceX rocket launch overnight from Cape Canaveral: Everything to know

SWI Editorial Staff2026-04-13T02:00:48-07:00April 13, 2026|

This Week in Chancery: SpaceX Investor, Endeavor, CD&R Accord

SWI Editorial Staff2026-04-13T02:00:06-07:00April 13, 2026|

Amazon get strict on Reference Pricing

SWI Editorial Staff2026-04-13T01:59:50-07:00April 13, 2026|

Related Post